Additionally, cases of ALK-rearranged NSCLC resistant to the 2G ALK-TKI ceritinib displaying features such as spindled cell shape, loss of E-cadherin immunostaining, and Vimentin overexpression, consistent with EMT, have been documented [209]. Here, ALK is linked to non-small cell lung carcinoma.